Lexaria's DehydraTECH Targets Side Effects In GLP-1 Market, Offers Relief For Semaglutide, Tirzepatide, And Liraglutide Users

The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effects

DehydraTECH reduces side effects and could support patient retention and further industry growth

DehydraTECH is the only technology publicly disclosed for its ability to reduce side effects in all 3 of the top GLP-1 drugs currently sold in the world today: semaglutide, tirzepatide, and liraglutide

KELOWNA, BC / ACCESS Newswire / July 23, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") strategic update as the industry continues to outperform earlier revenue growth projections.

Global pharmaceutical corporations are competing desperately to secure either a foothold, or dominance, in what is currently the fastest growing pharmaceutical sector in the world: GLP-1 weight loss and diabetes control. Lexaria previously reported, on November 7, 2024, that growth expectations for the GLP-1 industry supported revenues in excess of $100 billion per year.

As time has passed, this projection now seems out-of-date and overly conservative. The latest projections are that the GLP-1 industry will be generating over $156 billion in revenue as soon as 2030. Having generated $53.5 billion in 2024, stunning growth of 31% is expected in a single year, and projected revenues in 2025 are now expected to reach $70.1 billion. That represents an additional $1.38 billion in revenue per month in 2025 vs. 2024.

Despite remarkable revenue growth, however, there is a significant problem still plaguing the GLP-1 industry: unwanted adverse effects ("AEs") led by gastrointestinal issues, namely nausea, vomiting, diarrhea and constipation.

One study showed that between 47% and 64% of GLP-1 users with type 2 diabetes discontinued use of their GLP-1 drug within 1 or 2 years, respectively with gastrointestinal AEs having been cited as the main cause linked to the discontinuation rates. If roughly half of the patients using GLP-1 drugs discontinue use, the industry is faced with potential loss of tens of billions of revenue dollars per year.

For example, the leading GLP-1 brand in 2024 was Ozempic with 34% market share, which uses the drug semaglutide. Amalgamating AE data from four recent Novo Nordisk® ("Novo") GLP-1 studies that examined semaglutide and CagriSema, (Oasis 4; Step Up; Redefine1; Redefine 2) across a total of 4,218 persons, Novo reported that 75.7% of people experienced gastrointestinal AEs.